These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17850508)

  • 41. Autoimmune aspects of depigmentation in vitiligo.
    Le Poole IC; Wañkowicz-Kaliñska A; van den Wijngaard RM; Nickoloff BJ; Das PK
    J Investig Dermatol Symp Proc; 2004 Jan; 9(1):68-72. PubMed ID: 14870989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.
    Mantovani S; Garbelli S; Palermo B; Campanelli R; Brazzelli V; Borroni G; Martinetti M; Benvenuto F; Merlini G; della Cuna GR; Rivoltini L; Giachino C
    J Invest Dermatol; 2003 Aug; 121(2):308-14. PubMed ID: 12880423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of circulating CD8+T cells expressing skin homing and cytotoxic molecules in active non-segmental vitiligo.
    Zhang BX; Lin M; Qi XY; Zhang RX; Wei ZD; Zhu J; Man MQ; Tu CX
    Eur J Dermatol; 2013; 23(3):331-8. PubMed ID: 23782916
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A reactive ortho-quinone generated by tyrosinase-catalyzed oxidation of the skin depigmenting agent monobenzone: self-coupling and thiol-conjugation reactions and possible implications for melanocyte toxicity.
    Manini P; Napolitano A; Westerhof W; Riley PA; d'Ischia M
    Chem Res Toxicol; 2009 Aug; 22(8):1398-405. PubMed ID: 19610592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin?
    Prignano F; Betts CM; Lotti T
    J Electron Microsc (Tokyo); 2008 Jan; 57(1):25-31. PubMed ID: 18174263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic implications of autoimmune vitiligo T cells.
    Oyarbide-Valencia K; van den Boorn JG; Denman CJ; Li M; Carlson JM; Hernandez C; Nishimura MI; Das PK; Luiten RM; Le Poole IC
    Autoimmun Rev; 2006 Aug; 5(7):486-92. PubMed ID: 16920575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy.
    van den Boorn JG; Picavet DI; van Swieten PF; van Veen HA; Konijnenberg D; van Veelen PA; van Capel T; Jong EC; Reits EA; Drijfhout JW; Bos JD; Melief CJ; Luiten RM
    J Invest Dermatol; 2011 Jun; 131(6):1240-51. PubMed ID: 21326294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris.
    Kotobuki Y; Tanemura A; Yang L; Itoi S; Wataya-Kaneda M; Murota H; Fujimoto M; Serada S; Naka T; Katayama I
    Pigment Cell Melanoma Res; 2012 Mar; 25(2):219-30. PubMed ID: 22136309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.
    Speeckaert R; van Geel N; Luiten RM; van Gele M; Speeckaert M; Lambert J; Vermaelen K; Tjin EP; Brochez L
    Anticancer Res; 2011 Nov; 31(11):3697-703. PubMed ID: 22110189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transcriptional profiling of melanocytes from patients with vitiligo vulgaris.
    Strömberg S; Björklund MG; Asplund A; Rimini R; Lundeberg J; Nilsson P; Pontén F; Olsson MJ
    Pigment Cell Melanoma Res; 2008 Apr; 21(2):162-71. PubMed ID: 18426409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do we have to pay more attention to vitiligo patients? Peculiar histopathological features of primary cutaneous melanoma preceded by vitiligo.
    Onsun N; Büyükbabani N; Ummetoğlu O; Cebeci F
    J Dermatol; 2009 Nov; 36(11):612-5. PubMed ID: 19878396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
    Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
    J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of tumor necrosis factor-α in the pathogenesis of vitiligo.
    Camara-Lemarroy CR; Salas-Alanis JC
    Am J Clin Dermatol; 2013 Oct; 14(5):343-50. PubMed ID: 23912226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Engineering a new mouse model for vitiligo.
    Manga P; Orlow SJ
    J Invest Dermatol; 2012 Jul; 132(7):1752-5. PubMed ID: 22695284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum miRNA expression profiles change in autoimmune vitiligo in mice.
    Shi YL; Weiland M; Lim HW; Mi QS; Zhou L
    Exp Dermatol; 2014 Feb; 23(2):140-2. PubMed ID: 24401108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Understanding mechanisms of vitiligo development in Smyth line of chickens by transcriptomic microarray analysis of evolving autoimmune lesions.
    Shi F; Kong BW; Song JJ; Lee JY; Dienglewicz RL; Erf GF
    BMC Immunol; 2012 Apr; 13():18. PubMed ID: 22500953
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
    Palermo B; Garbelli S; Mantovani S; Scoccia E; Da Prada GA; Bernabei P; Avanzini MA; Brazzelli V; Borroni G; Giachino C
    Eur J Immunol; 2005 Nov; 35(11):3153-62. PubMed ID: 16224813
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vitiligo and Autoimmune Thyroid Disorders.
    Baldini E; Odorisio T; Sorrenti S; Catania A; Tartaglia F; Carbotta G; Pironi D; Rendina R; D'Armiento E; Persechino S; Ulisse S
    Front Endocrinol (Lausanne); 2017; 8():290. PubMed ID: 29163360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transcriptome Analysis and Emerging Driver Identification of CD8+ T Cells in Patients with Vitiligo.
    Deng Q; Wei J; Zou P; Xiao Y; Zeng Z; Shi Y; Zhan Y; Zhang H; Tang B; Zeng Q; Xiao R
    Oxid Med Cell Longev; 2019; 2019():2503924. PubMed ID: 31885781
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vitiligo antibodies are not directed to tyrosinase.
    Xie Z; Chen D; Jiao D; Bystryn JC
    Arch Dermatol; 1999 Apr; 135(4):417-22. PubMed ID: 10206048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.